aTYR PHARMA (ATYR) Profit After Tax (2014 - 2026)

aTYR PHARMA (ATYR) has reported Profit After Tax for 13 consecutive years, with -$10.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax rose 47.24% year-over-year to -$10.3 million; the trailing twelve-month figure through Jun 2026 stood at -$60.8 million (up 8.82% YoY), and the FY2025 full-year result was -$74.1 million, down 15.78% from the prior year.
• Profit After Tax grew to -$10.3 million in Q2 2026 per ATYR's latest filing, from -$10.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$7.5 million in Q4 2022 and bottomed at -$25.7 million in Q3 2025.
• Historically, Profit After Tax has averaged -$14.2 million across 5 years, with a median of -$13.6 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Profit After Tax sank 96.21% in 2023, then jumped 47.24% in 2026.
• Over 5 years, Profit After Tax stood at -$7.5 million in 2022, then tumbled by 96.21% to -$14.8 million in 2023, then slipped by 1.4% to -$15.0 million in 2024, then advanced by 6.98% to -$13.9 million in 2025, then gained by 25.95% to -$10.3 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$10.3 million, -$10.8 million, and -$13.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.